We use third-party cookies that help us analyze how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. However, you can opt out of these cookies by checking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button. Once you opt out, you can opt in again at any time by unchecking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button.
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]
On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common [...]
Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
By Brittney Nichols, MPH, RN-BSN, Science and Research Specialist, GO2 for Lung Cancer New treatments, developments, and scientific breakthroughs are always one of the most exciting aspects of the annual American Society of Clinical Oncology (ASCO) conference, but this [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
Ask the Experts: When should I talk to my doctor about clinical trials? You and your doctor might want to consider joining a clinical trial any time you must decide about your treatment such as at initial diagnosis, upon [...]
Ask the Experts: "I have small cell lung cancer and my doctor mentioned the option of having prophylactic cranial irradiation (PCI) to help prevent the cancer from spreading to my brain. I know some people decide to have PCI [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung [...]
